RESEARCH MONOGRAPH · KDC-MN-1322

Remimazolam

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

74/100

The benzodiazepine that finally got the propofol kinetics. Genuinely interesting molecule

Honestly, remimazolam is one of the more exciting clinical anesthesia introductions of the last decade and it's still underappreciated outside specialist circles. The design concept is simple: take a benzodiazepine pharmacophore (midazolam-like GABA-A potentiation through the alpha subunit), add an ester linkage that gets hydrolyzed rapidly by tissue carboxylesterases, and you get a benzodiazepine with propofol-like onset and offset kinetics. That worked.

The pharmacokinetics are the headline. Context-sensitive half-time stays under 10 minutes even after extended infusion, hydrolysis is mostly extrahepatic (tissue carboxylesterases), and the inactive carboxylic acid metabolite has no clinical activity. That kinetic profile is much closer to remifentanil than to midazolam, hence the name (it's literally 'remi' plus 'mazolam').

What makes it mechanistically interesting beyond the kinetics is the availability of flumazenil as a specific reversal agent. Propofol has no reversal. Etomidate has no reversal. Remimazolam can be reversed in minutes with a standard benzodiazepine antagonist. That's a meaningful safety advantage in procedural sedation where you want the deepest possible sedation but also need rescue if respiratory drive collapses.

The hemodynamic profile is reportedly more stable than propofol, particularly in cardiac-compromised patients, though the head-to-head data is mostly from the Sneyd and Wesselink RCTs and the Japanese phase 3 work. Not enormous outcome studies yet but the signal is clean.

For research use, remimazolam is the cleanest tool when you want benzodiazepine GABA-A potentiation with predictable washout kinetics. The Pharmacological Reviews and Clinical Pharmacokinetics writeups from 2020 to 2023 are good references.

Sourcing is the catch. It's relatively new (approved 2020 in the US), most research-grade material comes through a small number of suppliers, and the besylate salt is the standard formulation. Verify by HPLC and watch the ester hydrolysis rate in solution.

Staying power should be high. It hits a real clinical need (procedural sedation with reversibility) and the SAR concept is generalizable. We'd expect derivatives in the next decade.

Evidence: 78
Mechanism: 82
Reliability: 82
Safety: 82
Sourcing: 60
Value: 60
Signal: 70
Staying power: 80

Plain-language summary Intrigue 70 / 100

Remimazolam (Byfavo) is a clever soft-drug benzodiazepine designed to bring the sedation kinetics of propofol together with the safety reversibility of midazolam. FDA-approved in July 2020 for procedural sedation. The molecular trick is an ester linkage on the imidazole ring that gets hydrolyzed by tissue carboxylesterases to an inactive metabolite, bypassing the hepatic CYP3A4 metabolism that drags out midazolam's effects. Result: context-sensitive half-time after a four-hour infusion is about 7 to 8 minutes, versus over two hours for midazolam. Clinical onset is one to three minutes; cardiovascular and respiratory profile is the favorable benzodiazepine pattern (less hypotension and respiratory depression than equipotent propofol); flumazenil reverses it for any oversedation event. A genuinely well-engineered drug that solved a real clinical problem, even if the cost premium has slowed adoption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Ultrashort-acting benzodiazepine intravenous sedative

A soft drug benzodiazepine designed for ester hydrolysis by tissue esterases, FDA-approved 2020 for procedural sedation with the kinetics of propofol but the safety reversibility of midazolam.

Abstract

Remimazolam besylate (CAS 308242-62-8 free base; molecular formula C21H19BrN4O2 free base, molecular weight 439.31) is an ultrashort-acting benzodiazepine designed as a soft drug analog of midazolam, with an ester linkage on the 1-position imidazole substituent that is hydrolyzed by tissue carboxylesterases to the inactive carboxylic acid metabolite CNS7054. The compound was developed at Glaxo Group Research, advanced through Phase 3 by Cosmo Pharmaceuticals and PAION, and approved by the FDA in July 2020 (Byfavo) for procedural sedation. Mechanism is positive allosteric modulation of GABA-A receptors at the benzodiazepine site (alpha-1 subunit-containing receptors), identical to midazolam and other clinical benzodiazepines, with reversibility by flumazenil. Pharmacokinetics distinguish remimazolam from other benzodiazepines: the context-sensitive half-time after a 4-hour infusion is approximately 7 to 8 minutes (versus over 2 hours for midazolam), driven by tissue esterase hydrolysis that does not depend on hepatic CYP3A4 metabolism (the dominant midazolam pathway). The clinical effect is a sedation kinetic similar to propofol (rapid onset within 1 to 3 minutes, brief duration with minimal accumulation in extended infusions) combined with the favorable cardiovascular and respiratory profile of benzodiazepines (less hypotension, less respiratory depression than equipotent propofol) and the safety advantage of reversibility by flumazenil for any inadvertent oversedation. Approved indications are procedural sedation for upper endoscopy, colonoscopy, and bronchoscopy in adults. ICU sedation indications are under regulatory review in multiple jurisdictions; Japan and South Korea approved general anesthesia indications in 2020. Cost is currently substantially higher than midazolam.

Mechanism of action

GABA-A positive allosteric modulation at the benzodiazepine site (alpha-1 selective). Tissue esterase hydrolysis to inactive CNS7054 drives ultrashort context-sensitive half-time. Flumazenil-reversible.

Reported research dose ranges

Reported research dose ranges vary across the published literature.

References

Kilpatrick GJ, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology 2007.
Antonik LJ, et al. Phase I single ascending-dose study of remimazolam. Anesth Analg 2012.
Pastis NJ, et al. Remimazolam for moderate sedation during bronchoscopy. Chest 2019.

Read the full monograph

Available as a research-use-only PDF download.

KDC-MN-1322

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Remimazolam

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs